Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 4/20 | 0.73 |
| ▸ | ABL1 | P00519 | 8/20 | 0.72 |
| ▸ | BCR | P11274 | 6/20 | 0.72 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.71 |
| ▸ | LDLR | P01130 | 2/20 | 0.70 |
| ▸ | KIT | P10721 | 2/20 | 0.70 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.70 |
| ▸ | RAF1 | P04049 | 1/20 | 0.65 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.64 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13659898 | 0.91 | NR2E1 (0.77) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL23463453 | 0.89 | ABL1 (0.62) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL4254143 | 0.89 | NR2E1 (0.71) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL589522 | 0.88 | NR2E1 (0.73) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL29493483 | 0.88 | NR2E1 (0.73) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL4252904 | 0.88 | CSF1R (0.68) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL24532047 | 0.88 | NR2E1 (0.73) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL24070548 | 0.88 | NR2E1 (0.69) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL30211962 | 0.88 | NR2E1 (0.69) | NR2E1ABL1BCREPHB2LDLR | |
| SCHEMBL22065195 | 0.87 | EPHB2 (0.75) | NR2E1ABL1BCREPHB2LDLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | XIAMEN UNIVERSITY (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-2903614-B1 | NOVEL COMPOUNDS, THEIR SYNTHESIS AND THEIR USES | SPHAERA PHARMA PTE LTD (SG) | 2021-09-29 | — | — | EP | disclosed |
| EP-3663293-A1 | SUBSTITUTED PENTA- AND HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | Xiamen University (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | XIAMEN UNIVERSITY (CN) | 2020-05-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-10000470-B1 | Method for preparing nilotinib | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2018-06-19 | — | — | US | disclosed |
| US-10000470-B1 | Method for preparing nilotinib | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2018-06-19 | — | — | US | disclosed |
| US-20180148430-A1 | METHOD FOR PREPARING NILOTINIB | ASYMCHEM LABORATORIES (FUXIN) CO., LTD (CN) | 2018-05-31 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| US-8183248-B2 | Substituted pyrrolo[2,3-d]pyrimidines and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-05-22 | — | — | US | disclosed |
| EP-1899329-B1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-10-05 | — | — | EP | disclosed |
| EP-1891066-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-22 | — | — | EP | disclosed |
| EP-2186808-A1 | Salts of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide | Novartis AG (CH) | 2010-05-19 | — | — | EP | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2009-05-07 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| WO-2007010014-A2 | COMPOSITIONS FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS | VALENT PETER (AT) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007005673-A1 | PYRIMIDINE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | NR2E1 1030/4885ABL1 95/4885BCR 33/4885 |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | NR2E1 2044/4885ABL1 1/4885BCR 2/4885 |
| US-20090118273-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SRC, FYN, SYK | NR2E1 2043/4885ABL1 126/4885BCR 206/4885 |
| US-20180148430-A1 | METHOD FOR PREPARING NILOTINIB | ABL1, CDK19, ALK | NR2E1 3151/4885ABL1 1/4885BCR 76/4885 |
| US-11352354-B2 | Substituted penta-fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | PIKFYVE, PIK3CA, PIK3C2A | NR2E1 2578/4885ABL1 1429/4885BCR 1416/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | NR2E1 1030/4885ABL1 95/4885BCR 33/4885 |
| US-20200165246-A1 | SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF | PIKFYVE, PIK3CA, PIK3C2A | NR2E1 2578/4885ABL1 1429/4885BCR 1416/4885 |
| US-10000470-B1 | Method for preparing nilotinib | ABL1, CDK19, ALK | NR2E1 3151/4885ABL1 1/4885BCR 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.